Antimicrobial Resistance in Escherichia coli Strains From Urinary Tract Infections
Antimicrobial Resistance in Escherichia coli Strains From Urinary Tract Infections
复制标题
DOI：
10.1016/s0027-9684(15)31138-x
复制
发表时间：
2009-12-01
影响因子：
3.3
通讯作者：
Lamikanra, Adebayo
中科院分区：
文献类型：
--
作者：
Aboderin, Oladipo A.;Abdu, Abdul-Rasheed;Lamikanra, Adebayo
背景：近20年来，尿路感染(UTI)大肠埃希菌对多种不同药物的耐药性有所增加。本研究确定了大肠埃希菌对常用抗生素的耐药性趋势。对具有尿路感染特征的患者进行调查，以确定是否存在明显的菌尿。对尿液进行分离鉴定。结果：442例尿液标本中有158例(35.8%)有明显增长，其中41例(25.6%)为大肠埃希菌。在分离的大肠埃希菌中，药物敏感性由高到低依次为呋喃妥因(80%)、氧氟沙星(24%)、环丙沙星(15%)、奈利地酸(10%)、复方新诺明(5%)和阿莫西林/克拉维酸(2%)。没有分离株对阿莫西林、庆大霉素或四环素敏感。所有人还被发现对至少3种常用药物具有抗药性。所有25株产超广谱β-内酰胺(ESBC)的菌株均为产超广谱β-内酰胺酶(ESBCs)的菌株。结论：结果表明，大肠埃希菌对呋喃妥因的敏感性持续存在，对阿莫西林、庆大霉素、复方新诺明、环丙沙星、氧氟沙星和四环素的耐药性普遍增加。呋喃妥因是一种，在这个地区，可能是唯一一种经验性治疗简单尿路感染的药物。在这种环境下，有必要对产ESBC的大肠埃希菌在UTI中的参与进行全面的研究。
Background: An increase in resistance against many different drugs among urinary tract infection (UTI) E coli isolates has been observed in the last 2 decades. This study determined the trends of antimicrobial resistance in E coli to commonly used antibiotics.Methods: The study was conducted in Ile-Ife, southwest Nigeria. Patients with features suggestive of UTI were investigated for presence of significant bacteriuria. Urine isolates were identified. Antimicrobial susceptibility was evaluated in accordance with standard bacteriological methods.Results: Of 442 urine specimens, 158 (35.8%) yielded significant growth, including 41 (25.6%) with E coli. Among the E coli isolates, antimicrobial susceptibility varied in prevalence by agent in descending order as follows: nitrofurantoin (80%), ofloxacin (24%), ciprofloxacin (15%), nalidixic acid (10%), cotrimoxazole (5%), and amoxicillin/clavulanic acid (2%). No isolate was susceptible to amoxicillin, gentomicin, or tetracycline. All were also found to be resistant to at least 3 commonly used drugs. All 25 isolates tested for extended-spectrum beta-lactamose (ESBC) production were found to be presumptive ESBCs producers.Conclusion: The results demonstrate the continued susceptibility of E coli to nitrofurantoin and their widespread and increasing resistance to amoxicillin, gentamicin, cotrimoxazole, ciprofloxacin, ofloxacin, and tetracycline. Nitrofurantoin is a-and, in this locale, perhaps the only-fational drug for empiric treatment of uncomplicated UTI. There is a need for a comprehensive study of the involvement of ESBC-producing E coli in UTI in this environment.